Journal of Medicinal Chemistry p. 234 - 240 (1995)
Update date:2022-09-26
Topics:
Houlihan, William J.
Munder, Paul G.
Handley, Dean A.
Cheon, Seung H.
Parrino, Vincent A.
A series of 5-aryl-2,3-dihydroimidazo<2,1-a>isoquinolines previously reported to be platelet activating factor (PAF) receptor antagonist were evaluated for potential antitumor activity.Several compounds, such as the 5-(4'-tert-butylphenyl) (65), 5-<4'-(trimethylsilyl)phenyl> (69), and 5-(4'-cyclohexylphenyl) (71) analogs showed very good cytotoxicity against several tumor cell lines. 5-<4'-(Piperidinomethyl)phenyl>-2,3-dihydroimidazo<2,1-a>isoquinoline (SDZ 62-434, 53) was more effective on a milligram per kilogram basis than the clinical cytostatic agent edelfosine (1) in increasing survivors and decreasing tumor volume in the oral mouse Meth A fibrosarcoma assay.It was selected for further development and is currently in phase I clinical trials in cancer patients.
View MoreHefei Lifeon Pharmaceutical Co., Ltd.
Contact:+86-551-65328450
Address:No522 Wangjiang West Road
Changzhou Ruiping Chemical Co., Ltd
website:http://www.wishchem.com
Contact:+86-519-82324280
Address:No.288-1 Huacheng Road, Jintan
Qingdao Kylin Trading Co., Ltd.
Contact:0086-532-68979884/58972912/68972263/65/88171519
Address:Room 2308,A building International Trade Center No.230 Changjiang Middle Road of Qingdao Economic Development Zone,Shandong,China.
Changzhou Sunsheng Chem Co., Ltd
Contact:+1-(989)-854-0648
Address:No. 28 Yinshan Rd., Xixiashu Industrial Park
Shanghai PotentPharm Science and Technology Co.,Ltd
Contact:86-021-51969655
Address:Unit B, Building 18, No.300, Chuantu Rd,Pudong District, Shanghai 201202, China
Doi:10.1021/jo00310a014
(1990)Doi:10.1016/j.chempr.2017.10.007
(2017)Doi:10.1021/acs.jmedchem.0c00566
(2020)Doi:10.1246/bcsj.59.1277
(1986)Doi:10.1016/j.ejmech.2011.01.051
(2011)Doi:10.1021/ja2026882
(2011)
